References
- Kreger B E, Craven D E, McGabe W R. Gram‐negative bacteremia IV. Re‐evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68: 344–355
- Galpine J F. Chloramphenicol in typhoid fever. Br Med J 1949; 2: 1047–1048
- Spink W W, Braude A I, Casteneda M R, Goytia R S. Aureomycin therapy in human brucellosis due to Brucella melitensis. JAMA 1948; 138: 1145–1148
- Hopkin B DA. Too‐rapid destruction of gram‐negative organisms. Lancet 1977; 2: 603–604
- Hopkin B DA. Frapper fort ou doucement: a gram‐negative dilemma. Lancet 1978; 2: 1193–1194
- Hopkin B DA. A nasty shock from antibiotics. Lancet 1985; 2: 594
- Cohen J, McConnell J S. Release of endotoxin from bacteria exposed to ciprofloxin and its prevention with polymyxin B. Eur J Clin Microbiol 1986; 5: 13–17
- Cohen J, McConnell J S. Antibiotic induced endotoxin release. Lancet 1985; 1069–1070
- McConnel J S, Cohen J. Release of endotoxin from Escherichia coli by quinolones. J Antimicrob Chemother 1986; 18: 765–773
- Shenep J L, Barton R P, Mogan K A. Role of antibiotic class in the rate of liberation of endotoxin during the therapy for experimental gram‐negative bacterial sepsis. J Infect Dis 1985; 151: 1012–1018
- Tauber M G, Shibl A T, Hackbarth C J, Larrick J W, Sande M A. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits. J Infect Dis 1987; 156: 456–462
- Røkke O, Revhaug A, Osterud B, Giercksky K E. Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: The effect of antibiotic administration. Prog Clin Biol Res 1988; 272: 247–262
- Andersen B M, Solberg O. Effect of benzylpenicillin in mice infected with endotoxin‐liberating or non‐liberating variant strains of Neisseria meningitidis. Scand J Infect Dis 1984; 16: 257–266
- Shenep J L, Flynn P M, Barrett F F, Stidham G L, Westenkirchner D F. Serial quantitation of endotoxemia and bacteremia during the therapy for gram‐negative bacterial sepsis. J Infect Dis 1988; 157: 565–568
- Johnston C A, Greisman S E. Endotoxemia induced by antibiotic therapy: a mechanism for adrenal corticosteroid protection in gram‐negative sepsis. Trans Assoc Am Physicians 1984; 97: 172–181
- Elliott T SJ, Eley A, Colishaw A. Stability of tobramycin in combinations with selected new beta‐lactam antibiotics. JAC 1986; 17: 680–681
- Dofferhoff A SM, Bom V JJ, de Vries‐Hospers H G, van Ingen J, Meer J, Hazenberg B PC, Mulder P OM, Weits J. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor (PAI) and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1991, In press
- Neu H C. Relation of structural properties of beta‐lactam antibiotics to antibacterial activity. Am J Med 1985; 79(Suppl 2A)2–13
- Tuomanen E, Gilbert K, Tomasz A. Modulation of bacteriolysis by cooperative effects of penicillin‐binding proteins 1a and 3 in Escherichia coli. Antimicrob Agents Chemother 1986; 30: 659–663
- Cannon J G, Tompkins R G, Gelfland J A, Michie H R, Stanford G G, vd Meer J WM, Endress S, Lonneman G, Corsetti J. Circulating interleukin‐1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79–84
- Michalek S M, Morre R N, McGhee J R, Rosenstreich D L, Mergenhagen S E. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980; 141: 55–63
- Dofferhoff A SM, Bom V JJ, van Ingen J, de Vries‐Hospers H G, Hazenberg B PC, Meer J, Mulder P OM, Weits J. Patterns of cytokines, plasma endotoxin, and acute phase proteins during the treatment of severe sepsis in humans. Bacterial endotoxins: Cytokine mediators and new therapies for sepsis, A Sturk, S JH van Deventer, J ten Cate, H R Bulier, L G Thijs, J Levin. Wiley‐Liss, New York 1991; 43–54
- Cross A S, Sadoff J C, Bernton K E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor α/cachectin and murine interleukin 1 a protects mice from lethal bacterial infection. J Exp Med 1989; 169: 2021–2027
- Roll J T, Young K M, Czuprynski C J. Human rTNF‐alpha augments anti‐bacterial resistance in mice: potentation of its effects by recombinant human rIL‐1‐alpha. Immunology 1990; 69: 316–322
- Havell E A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894–2899
- Young L S. Endotoxins and mediators, an introduction. Circ Shock 1990; 31: 241
- Rothstein J L, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci USA 1988; 85: 607–611